BackLyell Immunopharma Overview
Lyell Immunopharma Inc

Lyell Immunopharma Target Price

See Lyell Immunopharma's analyst price targets ($34) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.07

Average Target Price

$34.00274.9% upside

1 analysts in the last 4 months

High: $34 | Low: $34

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14RBC Capital$34274.9% upsideOpen
2026-06-03Needham$45396.1% upsideOpen
2026-04-30Robert W. Baird$49440.2% upsideOpen
2026-04-10Needham$44385.1% upsideOpen
2025-12-09H.C. Wainwright$45396.1% upsideOpen
2025-11-24H.C. Wainwright$20120.5% upsideOpen
2024-10-30Bank of America SecuritiesGeoff Meacham$189% downsideOpen
2022-11-14Morgan Stanley$722.8% downsideOpen
2022-05-24Goldman Sachs$1232.3% upsideOpen

Lyell Immunopharma (LYEL) FAQ

As of the most recent data, LYEL shows a target price of $34. Scroll down for historical charts and peer comparison views.

If Lyell Immunopharma moved to the average analyst target of $34, shares would be roughly 274.9% higher than $9.07. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Lyell Immunopharma's earnings trajectory.

Besides this target price page, Stockcircle has Lyell Immunopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $34) with ownership activity and broader fundamentals.

Lyell Immunopharma's target price is $34; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.